Etesevimab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Etesevimab
DrugBank Accession Number
DB15897
Background

Etesevimab (LY-CoV016, also known as JS016) is a fully human and recombinant monoclonal antibody that targets the SARS-CoV-2 surface spike protein receptor binding domain.1,2

Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
  • Etesevimab
External IDs
  • CB6
  • JS016
  • LY-3832479
  • LY-CoV016
  • LY3832479
  • NP005
  • WHO 11873

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action

Etesevimab aims to neutralize SARS-CoV-2 by specifically binding to the virus' surface spike protein receptor binding domain. This high affinity binding then prevents SARS-CoV-2 from binding to the ACE2 host cell surface receptor. Etesevimab is currently being investigated against COVID-19.

TargetActionsOrganism
ASpike glycoprotein
binder
SARS-CoV-2
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
EtesevimabInjection, solution35 mg/1mLIntravenousEli Lilly and Company2021-02-09Not applicableUS flag
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
EtesevimabEtesevimab (35 mg/1mL)Injection, solutionIntravenousEli Lilly and Company2021-02-09Not applicableUS flag

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
N7Q9NLF11I
CAS number
2423948-94-9

References

General References
  1. Lilly Investors: Lilly provides comprehensive update on progress of SARS-CoV-2 neutralizing antibody programs [Link]
  2. Junshi Biosciences: Junshi Biosciences Announces Completion of Enrollment in Phase I Trial of JS016 [Link]
RxNav
2477854

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedPreventionCoronavirus Disease 2019 (COVID‑19)1
3RecruitingOtherCoronavirus Disease 2019 (COVID‑19)1
2Active Not RecruitingTreatmentCoronavirus Disease 2019 (COVID‑19)1
2, 3Active Not RecruitingTreatmentCoronavirus Disease 2019 (COVID‑19)1
1CompletedBasic ScienceHealthy Subjects (HS)2
1RecruitingTreatmentCoronavirus Disease 2019 (COVID‑19)1
1RecruitingTreatmentCoronavirus Disease 2019 (COVID‑19) / COVID-19; and High Infection Risk of SARS-CoV-21

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, solutionIntravenous35 mg/1mL
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Targets

Drugtargets2
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
SARS-CoV-2
Pharmacological action
Yes
Actions
Binder
General Function
Spike protein S1 attaches the virion to the cell membrane by interacting with host receptor, initiating the infection. Binding to human ACE2 receptor and internalization of the virus into the endosomes of the host cell induces conformational changes in the Spike glycoprotein (PubMed:32142651, PubMed:32075877, PubMed:32155444). Uses also human TMPRSS2 for priming in human lung cells which is an essential step for viral entry (PubMed:32142651). Can be alternatively processed by host furin (PubMed:32362314). Proteolysis by cathepsin CTSL may unmask the fusion peptide of S2 and activate membranes fusion within endosomes.
Specific Function
Host cell surface receptor binding
Gene Name
S
Uniprot ID
P0DTC2
Uniprot Name
Spike glycoprotein
Molecular Weight
141177.29 Da
References
  1. Lilly Investors: Lilly provides comprehensive update on progress of SARS-CoV-2 neutralizing antibody programs [Link]
  2. Junshi Biosciences: Junshi Biosciences Announces Completion of Enrollment in Phase I Trial of JS016 [Link]

Drug created on October 07, 2020 16:21 / Updated on March 04, 2021 09:26